Is NCT07050732 recruiting in Baltimore, MD?

Yes, NCT07050732 is currently recruiting participants at its Baltimore, MD location. This respiratory syncytial virus (rsv) clinical trial is actively enrolling qualified participants.

How do I join the respiratory syncytial virus (rsv) clinical trial in Baltimore?

To join this clinical trial in Baltimore, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Baltimore clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Respiratory Syncytial Virus (RSV) Clinical Trial in Baltimore, MD

About This Respiratory Syncytial Virus (RSV) Study in Baltimore

This clinical trial is being done to learn more about how well a vaccine (Arexvy®) for respiratory syncytial virus, also known as RSV, works in people with weakened immune systems. The main questions it aims to answer are: * Does 1 or 2 doses of Arexvy work better in people with weakened immune systems? * What medical problems do participants have after receiving Arexvy? Participants with weakened immune systems will: * Receive 3 study vaccines over the course of 1 year * Keep a diary of symptoms for 7 days after each vaccine * Have 3 in-person follow up study visits for checkups and tests over the course of 1.5 years * Have 6 phone follow up study visits over the course of 1.5 years

Sponsor: Johns Hopkins University

Who Can Participate

Inclusion Criteria

Able to understand and provide informed consent

Willing and able to comply with the requirements and restrictions in the protocol, including study visits and study-related procedures

Medically stable in the opinion of the Investigator at the time of first study vaccination

Life expectancy ≥ 365 days in the opinion of the Investigator at the time of first study vaccination

Included in at least one of the groups below:

Cellular therapy recipients (CTR):

Individuals ≥ 18 years of age at the time of first study vaccination

History of at least one of the following: i. Autologous stem cell transplant received more than 90 days prior to first study vaccination, ii. Allogeneic stem cell transplant received more than 90 days prior to first study vaccination, iii. Chimeric antigen receptor T cell (CAR-T) therapy received more than 90 days prior to first study vaccination

Solid organ transplant recipients (SOTR):

Individuals ≥ 18 years of age at the time of first study vaccination

Received an ABO-compatible, single-organ type, solid organ transplant (lung, heart, kidney, liver) at least 90 days prior to first study vaccination, and are on at least 2 systemic immunosuppressive agents at time of first study vaccination

Healthy comparator (HC):

Individuals ≥ 60 years of age at the time of first study vaccination or 50-59 years of age at the time of first study vaccination and at increased risk of severe RSV disease

No history of (a) or (b) above, and considered healthy or with chronic and stable medical conditions in the opinion of the Investigator, without immune compromise

Participants of childbearing potential if practicing adequate contraception or abstinence from 1 month prior to first study vaccination and agree to continue adequate contraception or abstinence through at least 1 month after last study vaccination. All participants of childbearing potential must have a negative pregnancy test on the day of first study vaccination, prior to administration.

Exclusion Criteria

Known history of hypersensitivity to any vaccine or history of a life-threatening reaction to a vaccine

Previous vaccination with any licensed or investigational RSV vaccine

Acute or chronic clinically significant/unstable neurological disease (such as uncontrolled seizures, strokes, Guillain-Barré Syndrome (GBS)

Vaccination with any inactivated, subunit, or split influenza vaccine or COVID-19 vaccine within 14 days prior to first study vaccination, or vaccination with any other licensed or investigational vaccine within 30 days prior to first study vaccination

Receipt of investigational or approved monoclonal antibodies against RSV within 90 days prior to first study vaccination

Moderate or severe acute illness/infection (in opinion of the Investigator) or febrile illness (temperature ≥ 38.0°C \[≥ 100.4°F\]) on the day of first study vaccination. A prospective participant should not be enrolled in the study until the condition has resolved or the febrile event has subsided.

Any medical condition that in the opinion of the Investigator would make intramuscular injection unsafe

Receipt of immunoglobulins or plasma products within 90 days prior to first study vaccination

Receipt of B-cell depleting medications (e.g., Rituximab, ocrelizumab, ofatumumab, belimumab, epratuzumab, antithymocyte globulin) within 90 days prior to first study vaccination

Currently pregnant or breastfeeding or planning to become pregnant, discontinue contraception, or breastfeed during the study period

Any of the following:

Cellular therapy recipients (CTR):

Graft-versus-host disease (GVHD) requiring systemic treatment with at least 0.5 mg/kg per day of prednisone or equivalent at time of first study vaccine

Solid organ transplant recipients (SOTR):

History of any of the following within 90 days prior to first study vaccination: allograft rejection, post-transplant lymphoproliferative disease, treatment for either of these conditions

Healthy comparator (HC):

Any confirmed/suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive or cytotoxic therapy, based on medical history

Any other conditions which, in the opinion of the Investigator, may pose additional risks from participation in the study, may interfere with the individual's ability to comply with study requirements or may impact the quality or interpretation of the data obtained from the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Baltimore?

Yes, this clinical trial (NCT07050732) has an active research site in Baltimore, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Respiratory Syncytial Virus (RSV) Treatment Options in Baltimore, MD

If you're searching for respiratory syncytial virus (rsv) treatment options in Baltimore, MD, this clinical trial (NCT07050732) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Baltimore research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced respiratory syncytial virus (rsv) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all respiratory syncytial virus (rsv) clinical trials near you to find additional studies recruiting in your area.

Respiratory Syncytial Virus (RSV) Clinical Trial in Baltimore, MD

Expert Care in Baltimore

IRB Approved

No-Cost Care

Apply for This Baltimore Location

Why Participate?

Simple Process